The RIO study tested whether broadly neutralizing antibodies could safely replace daily HIV therapy. In a rigorously designed trial, 75% of participants maintained viral suppression for 20 weeks after stopping antiretrovirals. The findings mark a pivotal step toward potential HIV remission and more flexible treatment strategies.

In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.

Dr. Sarah Fidler discusses the challenges of lifelong antiretroviral therapy for HIV and the need for alternative approaches. She highlights broadly neutralising antibodies (bNAbs) as a promising strategy that targets the virus and dormant infected cells, potentially enabling longer-term control by harnessing the immune system’s memory without daily medication.

Dr. Ikechukwu B. Moses, winner of the ESCMID Global 2025 Emerging Young Investigator Award, explores antimicrobial resistance through a One Health lens. His work spans zoonotic pathogen transmission, bacteriophage therapy, and AI-driven genomic research, aiming to reduce antibiotic reliance and translate lab-based innovations into scalable, real-world clinical and veterinary solutions.

Dr Dariusz Hareza reflects on ESCMID Global 2025, highlighting its international scope, informal collaboration, and key themes in antimicrobial resistance. He discusses impactful sessions on global surveillance, Kazakhstan’s primary care initiatives, and novel approaches like CRISPR and AI, all pointing toward an innovative and integrated future in infectious diseases.

The US Food and Drug Administration (FDA) has approved the first virus-like particle (VLP) chikungunya vaccine PXVX0317 (VIMKUNYA™), for individuals aged 12 years and older, with Bavarian Nordic recently announcing its commercial launch.1,2 This approval addresses a critical unmet need for ...

Dr Simon Feys discusses his award-winning research on viral-associated pulmonary aspergillosis (VAPA) in critically ill patients, highlighting key insights into its pathophysiology, diagnostic challenges, and treatment gaps. His work combines clinical expertise with multi-omics analysis to improve understanding, detection, and management of this often-overlooked but potentially deadly fungal superinfection.

Dr Simon Feys discusses his journey into intensive care medicine, driven by the complexity and impact of treating critically ill patients. He highlights the central role of infections in ICU, the importance of broad medical knowledge, and how clinical experience and research together shape his approach to patient care and innovation.

Dr. Jon Salmanton-García discusses unmet needs in preventing and treating respiratory infections in haematology patients, highlighting real-world data insights and the urgent need for targeted vaccines and antivirals.